Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

FDA Clears New Targets for Luminex GI Pathogen Panel

by Global Biodefense Staff
October 1, 2014
E. coli bacteria

E. coli bacteria

Luminex Corporation this week announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel (GPP).

The new targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae.

As the first multiplexed U.S. IVD cleared test for infectious gastroenteritis, xTAG GPP simultaneously detects 14 common viral, bacterial, and parasitic causative pathogens from a single patient sample.

The xTAG GPP panel now detects the following potential causes of gastroenteritis:

  • Campylobacter
  • Clostridium difficile toxin A/B
  • Escherichia coli (E. coli) O157
  • Enterotoxigenic E. coli (ETEC) LT/ST
  • Salmonella
  • Shigella
  • Shiga-like Toxin producing E. coli (STEC) stx 1/stx 2
  • Vibrio cholerae, cholera toxin gene (ctx)
  • Adenovirus 40/41
  • Norovirus
  • Rotavirus A
  • Cryptosporidium
  • Entamoeba histolytica
  • Giardia

By testing for greater than 90% of the causative pathogens of infectious gastroenteritis in a single test, clinicians can more quickly identify and treat the causative agent. Additionally co-infections can be more easily identified.

Simultaneous molecular testing on a single sample within a single shift also provides significant benefits to laboratories in terms of workflow and resource utilization. The ability to scale throughput by processing 96-well plates allows laboratories to easily tailor their sample processing to physician demand.

In addition, the company announced FDA has cleared the panel for use with specimens in Cary-Blair medium, a common transport medium for collection and preservation of microbiological specimens.

“We are pleased to receive clearance for this new specimen medium and these additional clinical targets which provide even more flexibility to our customers,” said Patrick J. Balthrop, president and chief executive officer of Luminex. “As laboratories are being asked to do more with less, we are continually working to deliver solutions that meet the varied needs of our customers.”

Source: Luminex press release, adapted. xTAG is a registered, protected term of Luminex.

Tags: AdenovirusC. diffCampylobacterE. coliNorovirusSalmonellaShigella

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC